- Home
- ATRC
ATRC
AtriCure Inc.
as of 12-10-2025 2:37pm EST
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | MASON |
| Market Cap: | 1.6B | IPO Year: | 2005 |
| Target Price: | $52.00 | AVG Volume (30 days): | 543.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.29 - $43.11 | Next Earning Date: | 10-29-2025 |
| Revenue: | $518,304,999 | Revenue Growth: | 15.80% |
| Revenue Growth (this year): | 16.9% | Revenue Growth (next year): | 12.29% |
AI-Powered ATRC Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of AtriCure Inc. (ATRC)
Chief Mktg & Strategy Officer
Avg Cost/Share
$37.29
Shares
5,166
Total Value
$192,640.14
Owned After
78,798
SEC Form 4
Director
Avg Cost/Share
$38.00
Shares
4,967
Total Value
$188,746.00
Owned After
34,374
SEC Form 4
Director
Avg Cost/Share
$37.32
Shares
5,033
Total Value
$187,831.56
Owned After
34,374
SEC Form 4
Director
Avg Cost/Share
$35.72
Shares
3,000
Total Value
$107,160.00
Owned After
11,371
SEC Form 4
Chief Mktg & Strategy Officer
Avg Cost/Share
$36.30
Shares
3,000
Total Value
$108,900.00
Owned After
78,798
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Noznesky Justin J | ATRC | Chief Mktg & Strategy Officer | Nov 26, 2025 | Sell | $37.29 | 5,166 | $192,640.14 | 78,798 | |
| WEHRWEIN SVEN | ATRC | Director | Nov 25, 2025 | Sell | $38.00 | 4,967 | $188,746.00 | 34,374 | |
| WEHRWEIN SVEN | ATRC | Director | Nov 24, 2025 | Sell | $37.32 | 5,033 | $187,831.56 | 34,374 | |
| Yuen Maggie | ATRC | Director | Nov 21, 2025 | Sell | $35.72 | 3,000 | $107,160.00 | 11,371 | |
| Noznesky Justin J | ATRC | Chief Mktg & Strategy Officer | Sep 12, 2025 | Sell | $36.30 | 3,000 | $108,900.00 | 78,798 |
Compare ATRC vs Leading Stocks
See how ATRC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ATRC AtriCure Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.